pSivida gets Austrian approval for eye drug; IntelGenx starts trials for migraine film;

 @DamianFierce: Tamarisk plans to "turn the industry upside down" with oral insulin platform. News | Follow @DamianFierce

> pSivida ($PSDV) has received marketing authorization in Austria for Iluvien, a treatment for vision impairment using the company's back-of-the-eye delivery platform. The approval is a step toward EMA approval, the company said. Release

> IntelGenx has launched trials for VersaFilm, its anti-migraine oral film, in Canada. The goal is to establish safety and bioequivalency for a future FDA application. More

> PCI Biotech has partnered with Modulight to develop a medical laser system to trigger endosomal drug release into cancerous cells. Report

> An Army researcher has discovered a new way to carry vaccines that could have drug delivery implications. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.